{"prompt": "['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 82 of 122', 'maximum severity at the OLFC and by treatment group. The Cochran-Mantel-Haenszel', 'statistics with equally spaced scores (row mean score differences statistic) stratified by', 'country will be used to test for a treatment difference.', 'The proportion of subjects successfully completing the RWPC with no or mild symptoms', 'after approximately 13 months of AR101 treatment will be assessed by presenting the', 'response rate and the associated 95% CI using an exact Clopper-Pearson CI.', 'The maximum severity of symptoms during the RWPC after approximately 13 months of', 'AR101 treatment in eligible subjects who consented to the RWPC will be assessed by', 'tabulating the number and percentage of subjects by maximum severity.', 'Full details will be provided in the statistical analysis plan.', '10.8 Analysis of Safety', 'All safety analyses will be performed using the safety population. Safety data will be listed', 'and summarized by treatment received. Descriptive statistics will be used.', 'Safety data will be collected from signed informed consent/assent through early', 'discontinuation or study exit, and through at least 30 days after early discontinuation or study', 'exit for subjects with unresolved adverse events or through at least 6 months after early', 'discontinuation or study exit for subjects with GI adverse events of interest.', 'Adverse events will be classified by system organ class and coded to preferred term using the', 'Medical Dictionary for Regulatory Activities (MedDRA). Adverse events will be classified', 'by severity using the CoFAR grading system for allergic reactions, EAACI guidelines for', 'anaphylaxis, and CTCAE for all other adverse events (Section 8.4).', 'Summaries of the safety of AR101 treatment and standard of care alone during the study will', 'include the following:', 'Overall summary of adverse events', 'Incidence of all nonserious and serious adverse events', 'Incidence of adverse events by severity grade', 'AR101 treatment only:', '-', 'Incidence of adverse events during up-dosing and maintenance', '-', 'Incidence of adverse events with onset < 90 minutes after AR101 dosing at the', 'study site', '-', 'Incidence and severity of treatment-related adverse events', '-', 'Incidence of treatment-related adverse events during up-dosing and maintenance', '-', 'Incidence of treatment-related adverse events with onset < 90 minutes after', 'AR101 dosing at the study site']['Aimmune Therapeutics, Inc.', 'AR101', 'ARC009 Protocol Amend 1.0', '11 Apr 2018 - FINAL', 'Aimmune Confidential Information', 'Page 83 of 122', '-', 'Incidence of dose modifications', '-', 'Exposure-adjusted event rates for the most frequent treatment-related adverse', 'events (ie, adverse events in > 5% of the safety population)', 'Exposure-adjusted event rates for the most frequent adverse events (ie, adverse events', 'in > 5% of the safety population)', 'Incidence of early treatment discontinuation due to adverse events and due to chronic', 'or recurrent GI adverse events', 'Separate summaries will be presented for anaphylaxis, allergic reaction adverse', 'events, use of epinephrine, and accidental/nonaccidental food allergen exposure', 'Adverse events with onset before the first dose of AR101 treatment (or on day 1 for standard', 'of care alone) will be listed only.', 'All medications will be coded using the World Health Organization Drug Dictionary', '(WHO-DD). Medications will be listed and summarized by Anatomical Therapeutic', 'Chemical (ATC) classification system level 1 and preferred name.', 'Prior and concomitant medications, excluding rescue medications, will be', 'summarized separately by ATC class, preferred name, and treatment.', 'Rescue medications used during screening, initial dose escalation, up-dosing,', 'maintenance, and overall (including all rescue medications reported on the case report', 'form) will be summarized by ATC class, preferred name, and treatment received.', 'All prior, concomitant, and rescue medications will be listed by subject.', 'Summary statistics will be provided for the ACT, lung function data, and laboratory data if', 'relevant. These data will also be listed by subject.', 'Full details for the safety analyses will be provided in the statistical analysis plan.', '10.9 Other Analyses', 'Additional endpoints will be assessed over the course of the study as follows:', 'Changes from baseline in TNSS scores in subjects with pre-existing allergic rhinitis', 'Changes from baseline in SCORAD scores in subjects with pre-existing atopic', 'dermatitis', 'Changes in peanut SPT mean wheal diameters', 'Full details for these analyses will be provided in the statistical analysis plan.']\n\n###\n\n", "completion": "END"}